BCAX Stock Analysis: Buy, Sell, or Hold?
BCAX - Bicara Therapeutics Inc. Common Stock
$28.10
-0.05 (-0.18%)
▼
5d:
-7.57%
30d:
+32.05%
90d:
+26.92%
HOLD
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 11, 2026
26d
Get Alerted When BCAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BCAX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: BCAX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: BCAX is currently trading at $28.10, which is considered slightly high relative to its 30-day fair value range of $21.87 to $29.07.
Technical Outlook: Technically, BCAX is in a strong uptrend. The price is currently testing key support at $27.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $31.46 (+12.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BCAX is in a strong uptrend. The price is currently testing key support at $27.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $31.46 (+12.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$21.87 -
$29.07
Company Quality Score
61/100
(BUY)
Options IV Signal
3th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
71.7%
All Signals
- BULLISH: Options cheap (IV 3th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($31.46)
- CAUTION: Recommendation downgraded due to -7.6% 5-day decline
Trading Range Analysis
30-Day Trading Range
$21.87 -
$29.07
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$3.57
(12.7%)
Support & Resistance Levels
Support Level
$27.57
Resistance Level
$30.99
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.74
Wall Street Target
$31.46
(+12.0%)
Share & Embed Analysis
Last updated: July 14, 2026 9:24 PM ET
Data refreshes hourly during market hours. Next update: 10:24 PM
Data refreshes hourly during market hours. Next update: 10:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
Ivan Hyep
SELL
9200 shares
2026-04-21
Claire Mazumdar
SELL
15000 shares
2026-04-20
Ryan Cohlhepp
SELL
12500 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 60 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
